397 research outputs found

    Research activities in regional crop modelling and yield forecasting

    Get PDF
    CGMS is being applied successfully within the MARS Crop Yield Forecasting System for qualitative monitoring of the growing season and for making quantitative crop yield forecasts. Nevertheless, there are large uncertainties related to applying crop growth models over large areas

    UK Public Sector Information and Re-use Policy – A 2008 Analysis

    Get PDF
    INTRODUCTION: Earlier antiretroviral therapy (ART) initiation reduces HIV-1 incidence. This benefit may be offset by increased transmitted drug resistance (TDR), which could limit future HIV treatment options. We analyze the epidemiological impact and cost-effectiveness of strategies to reduce TDR. METHODS: We develop a deterministic mathematical model representing Kampala, Uganda, to predict the prevalence of TDR over a 10-year period. We then compare the impact on TDR and cost-effectiveness of: (1) introduction of pre-therapy genotyping; (2) doubling use of second-line treatment to 80% (50-90%) of patients with confirmed virological failure on first-line ART; and (3) increasing viral load monitoring from yearly to twice yearly. An intervention can be considered cost-effective if it costs less than three times the gross domestic product per capita per quality adjusted life year (QALY) gained, or less than 3420inUganda.RESULTS:TheprevalenceofTDRispredictedtorisefrom6.73420 in Uganda. RESULTS: The prevalence of TDR is predicted to rise from 6.7% (interquartile range [IQR] 6.2-7.2%) in 2014, to 6.8% (IQR 6.1-7.6%), 10.0% (IQR 8.9-11.5%) and 11.1% (IQR 9.7-13.0%) in 2024 if treatment is initiated at a CD4 <350, <500, or immediately, respectively. The absolute number of TDR cases is predicted to decrease 4.4-8.1% when treating earlier compared to treating at CD4 <350 due to the preventative effects of earlier treatment. Most cases of TDR can be averted by increasing second-line treatment (additional 7.1-10.2% reduction), followed by increased viral load monitoring (<2.7%) and pre-therapy genotyping (<1.0%). Only increasing second-line treatment is cost-effective, ranging from 1612 to 2234(IQR2234 (IQR 450-dominated) per QALY gained. CONCLUSIONS: While earlier treatment initiation will result in a predicted increase in the proportion of patients infected with drug-resistant HIV, the absolute numbers of patients infected with drug-resistant HIV is predicted to decrease. Increasing use of second-line treatment to all patients with confirmed failure on first-line therapy is a cost-effective approach to reduce TDR. Improving access to second-line ART is therefore a major priority

    Winning en cryoconservering van sperma van zeldzame Nederlandse konijnenrassen voor de genenbank

    Get PDF
    In dit rapport wordt beschreven welke activiteiten CGN in samenwerking met de SZH, KLN en individuele fokkers hebben ondernomen om genetisch materiaal van konijnenrassen veilig te stellen in de genenbank. Op basis van literatuur en praktijkervaringen is een protocol voor spermawinning en spermaverwerking (cryoconservering) vastgesteld. Een dergelijk protocol was niet beschikbaar in de Nederlandse bedrijfsmatige konijnenhouderij omdat daar uitsluitend met vers sperma gewerkt wordt en niet met ingevroren sperma. Het rapport eindigt met een beschrijving van de resultaten van de spermawinning

    Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry

    Get PDF
    __Background:__ Trials in castration-resistant prostate cancer (CRPC) treatment have shown improved outcomes, including survival. However, as trial populations are selected, results may not be representative for the real-world population. The aim of this study was to assess the differences between patients treated in a clinical trial versus standard care during the course of CRPC in a real-world CRPC population. __Design, setting, and participants:__ Castration-resistant Prostate Cancer Registry is a population-based, observational, retrospective registry. CRPC patients from 20 hospitals in the Netherlands have been included from 2010 to 2013. __Outcome measurements and statistical analysis:__ Baseline characteristics, systemic treatment, and overall survival were the main outcomes. Descriptive statistics, multivariate Cox regression, and multiple imputations with the Monte Carlo Markov Chain method were used. __Results and limitations:__ In total, 1524 patients were enrolled of which 203 patients had participated in trials at any time. The median follow-up period was 23 mo. Patients in the trial group were significantly younger and had less comorbidities. Docetaxel treatment was more freque
    corecore